Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.